Benitec Biopharma Inc. announced the first subject has been dosed in the BB-301 Phase 1b/2a Clinical Treatment Study. Dosing of the first subject marks the beginning of the 52-week follow-up period designed to facilitate inclusive evaluation of the primary and secondary endpoints of the BB-301 Phase 1ss/2a Clinical Treatment Study". Subjects enrolled in Benitec's ongoing OPMD Natural History (NH) study will become eligible to roll over into the BB-301 Phase 1 b/2a Clinical Treatment Study for the treatment of OPMD-related dysphagia after 6 months of baseline data collection.

Currently, there are 19 subjects enrolled into the NH study at the U.S. clinical trial site, with each subject having the potential to roll over into theBB-301 Phase 1b/2a Clinical Treatment Study. Interim safety and efficacy data are expected to become available from the BB-301 Phase 1B/2a Clinical Treatment Study in mid-2024.